Phase II study of first-line intensity-modulated radiotherapy (IMRT) followed by gemcitabine, dexamethasone, and cisplatin for high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: the GREEN study

Radiotherapy is the backbone for early-stage NKTCL, but relapses and systemic failures are common for patients with unfavorable factors. This is the first prospective phase II trial focusing on high-risk group of early-stage NKTCL, and also the first prospective study that applies IMRT to early-stage NKTCL. The present study suggests that first-line IMRT followed by GDP represents an effective and well-tolerated therapeutic approach with improved long-term survival and decreased failure rate for high-risk early-stage NKTCL.

https://ift.tt/2sdAdcC